PMID: 9426742Jan 14, 1998Paper

Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer

Urology
K C BalajiS Laxmanan

Abstract

To explore the possibility of using antisense oligonucleotide therapy for prostate cancer, we investigated the effect of c-myc-antisense-oligonucleotide (c-myc-As-ODN) in human prostate cancer cell lines such as LNCaP, PC3, and DU145. LNCaP, PC3, and DU145 cells were incubated in the presence of c-myc-As-ODN. Dose (0 to 10 microM) and time dependent (1 to 6 days) effects on proliferation and viability were examined by [3H]thymidine incorporation and MTT assay, respectively. Flow cytometry analysis was carried out to analyze cell cycle status by determining the DNA content in LNCaP cells. Control cultures received either c-myc-sense-ODN or scrambled (nonsense) nucleotides. Time- and dose-dependent decreases in DNA synthesis and cell viability were noted for all three prostate cancer cell lines after c-myc-As-ODN treatment. Further studies using LNCaP cells indicated that these changes were accompanied by an increase in the percentage of cells with less than 2N DNA content after c-myc-As-ODN treatment. The results suggest that c-myc-As-ODN induces cell death. Comparison of a c-myc-As-ODN-treated group with a group subjected to isoleucine deprivation revealed that thymidine incorporation was almost the same in c-myc-As-ODN-treated...Continue Reading

References

Nov 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·B C PariaG K Andrews
Jan 1, 1992·Cytometry·Z DarzynkiewiczF Traganos
May 11, 1992·The Journal of Clinical Investigation·J F CollinsG C Bagby
Dec 20, 1990·The Journal of Steroid Biochemistry and Molecular Biology·A L SchuurmansE Mulder
Dec 15, 1982·Biochemical and Biophysical Research Communications·G Prem veer Reddy
Apr 25, 1995·Proceedings of the National Academy of Sciences of the United States of America·T L BurgessT B Kramer
May 1, 1994·International Journal of Cancer. Journal International Du Cancer·H C WuL W Chung
Oct 1, 1996·Current Opinion in Immunology

❮ Previous
Next ❯

Citations

Jan 23, 2003·Current Urology Reports·Ingo Kausch, Andreas Böhle
Dec 4, 2008·Asian Journal of Andrology·Sachin AgrawalWilliam D Dunsmuir
Jan 5, 2002·Cancer Biotherapy & Radiopharmaceuticals·Y M ZhangD J Hnatowich
Jul 23, 2011·Genes & Cancer·Cheryl M KohAngelo M De Marzo
Mar 23, 2012·Journal of Carcinogenesis·Subhamoy DasguptaJamboor K Vishwanatha
Jan 19, 2016·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Cheryl M KohErnesto Guccione
Apr 29, 2008·Cancer Letters·Chulso MoonSaechul Kim
Oct 21, 2004·Cancer·David G BostwickBarry Timms
Sep 8, 2001·The Journal of Urology·K J HarringtonR G Vile
Jun 7, 2002·The Journal of Urology·I Kausch, A Böhle
Jun 11, 1999·The Urologic Clinics of North America·G S PalapattuA S Belldegrun
Dec 24, 2005·Expert Opinion on Drug Delivery·Sergey A Kaliberov, Donald J Buchsbaum
Aug 4, 2005·The Journal of Steroid Biochemistry and Molecular Biology·LaMonica V StewartNancy L Weigel
Oct 7, 2003·Oncogene·Annamaria BiroccioGabriella Zupi
Jul 13, 2002·Expert Review of Anticancer Therapy·Yehoshua GdorTimothy C Thompson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.